Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Juno Therapeutics Cmn (NASDAQ: JUNO)

$23.79 USD -$1.16 (-4.65%)
Last Price $23.79
Net Change $-1.16 (-4.65%)
Bid $0
Ask Price $0
Open Price $25
Previous Close Price $24.95
High Price $25.07
Low Price $23.66
Number of Trades 5,983
Volume 1,432,700
Fifty Two Week High $49.72 (2016-06-06)
Fifty Two Week Low $17.52 (2016-12-22)
Average Daily Volume 1,598,317
Share Outstanding 106,020 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $-0.65 (2017-03-01)
2nd Quarter Earnings $-0.57 (2016-11-09)
3nd Quarter Earnings $-0.64 (2016-08-04)
4th Quarter Earnings $-0.78 (2016-05-09)
PE Ratio $0
EPS Growth $-0.87
Recent Earnings $-0.65
Annual EPS $-2.68
Last Quarter EPS $
Market Capitalization $2.52B
Insider Shareholders % 0.1526%
Annual Revenue $0B
No. Shares Outstanding 106,020
Inst. Shareholder % 63.71%
Annual Net Income $0B
TTM Net Profit Margin $102.46
1-Year Return -46.52%
3-Year Return -32.03%
5-Year Return -32.03%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -0.87%
Dividends per Share $
Stock Split Ratio
Beta 2.36
Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.